Anebulo Pharmaceuticals, Inc. (ANEB) stock
ANEBNasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.00+0.00 (+75.00%)
Close on Oct 19, 2026Market cap $28.76KP/E –Yield –
Anebulo Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Anebulo Pharmaceuticals's total assets was $9.42M at Dec 31, 2025. For fiscal 2025 it was $12.15M, up 198.2% from the year before. The highest annual figure on record is $21.65M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $12.15M | +198.2% |
| FY2024 | Jun 30, 2024 | $4.07M | -65.1% |
| FY2023 | Jun 30, 2023 | $11.67M | -25.1% |
| FY2022 | Jun 30, 2022 | $15.58M | -28.1% |
| FY2021 | Jun 30, 2021 | $21.65M | +615.0% |
| FY2020 | Jun 30, 2020 | $3.03M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $9.42M | -40.5% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $10.70M | +333.6% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $12.15M | +198.2% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $14.01M | +133.6% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $15.84M | +111.2% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $2.47M | -72.7% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $4.07M | -65.1% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $6.00M | -58.5% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $7.50M | -55.6% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $9.05M | -54.3% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $11.67M | -25.1% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $14.43M | -16.3% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $16.89M | -10.9% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $19.82M | -3.3% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $15.58M | -28.1% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $17.25M | +301.9% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $18.96M | +526.2% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $20.50M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $21.65M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $4.29M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $3.03M | – |
See a number that looks wrong?